Evommune (NYSE:EVMN) Stock Rating Lowered by Wall Street Zen

Evommune (NYSE:EVMN) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

A number of other analysts have also recently commented on the stock. Zacks Research upgraded shares of Evommune to a “hold” rating in a research note on Tuesday, December 2nd. William Blair assumed coverage on shares of Evommune in a report on Monday, December 1st. They set an “outperform” rating on the stock. Leerink Partners started coverage on Evommune in a research report on Monday, December 1st. They issued an “outperform” rating and a $42.00 price target for the company. Leerink Partnrs raised shares of Evommune to a “strong-buy” rating in a report on Monday, December 1st. Finally, Evercore ISI started coverage on shares of Evommune in a research note on Monday, December 1st. They set an “outperform” rating and a $40.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $39.33.

Evommune Trading Up 0.2%

NYSE EVMN opened at $21.98 on Friday. Evommune has a 52 week low of $16.70 and a 52 week high of $24.03.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.